News articles about Cleveland BioLabs (NASDAQ:CBLI) have trended somewhat negative recently, according to Alpha One Sentiment Analysis. The research firm, a unit of Accern, identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of 0.00 on Alpha One’s scale. Alpha One also assigned media coverage about the biotechnology company an impact score of 100 out of 100, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted AlphaOne Sentiment’s analysis:
- The 3 Most Egregious Penny Stock Scams Exposed (moneymorning.com)
- Cleveland Biolabs Inc. Reports First Quarter 2017 Financial Results And Development Progress (biospace.com)
- Cleveland BioLabs, Inc. (CBLI) Posts Earnings Results (americanbankingnews.com)
- Cleveland BioLabs, Inc. (NASDAQ:CBLI) Files An 8-K Results of Operations and Financial Condition (4-traders.com)
- Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress (feeds.benzinga.com)
Shares of Cleveland BioLabs (NASDAQ:CBLI) traded up 2.39% during mid-day trading on Friday, reaching $3.43. The company had a trading volume of 131,028 shares. The stock has a 50 day moving average of $3.00 and a 200-day moving average of $1.97. Cleveland BioLabs has a one year low of $1.22 and a one year high of $5.55. The firm’s market capitalization is $37.69 million.
Cleveland BioLabs (NASDAQ:CBLI) last issued its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. Cleveland BioLabs had a negative net margin of 75.04% and a negative return on equity of 21.29%. The business had revenue of $0.58 million for the quarter. Equities analysts predict that Cleveland BioLabs will post ($0.16) EPS for the current year.
Cleveland BioLabs Company Profile
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.